PMID- 19854112
OWN - NLM
STAT- MEDLINE
DCOM- 20100216
LR  - 20131121
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 16
IP  - 3
DP  - 2009 Nov
TI  - Antiseizure effects of 3alpha-androstanediol and/or 17beta-estradiol may involve 
      actions at estrogen receptor beta.
PG  - 418-22
LID - 10.1016/j.yebeh.2009.09.008 [doi]
AB  - Testosterone (T), the principal androgen secreted by the testes, can have 
      antiseizure effects. Some of these effects may be mediated by T's metabolites. T 
      is metabolized to 3alpha-androstanediol (3alpha-diol). T, but not 3alpha-diol, 
      binds androgen receptor. We investigated effects of 3alpha-diol (1 mg/kg, SC) 
      and/or an androgen receptor blocker (flutamide 10 mg, SC), 1 hour prior to 
      administration of pentylenetetrazol (85 mg/kg, IP). Juvenile male rats 
      administered 3alpha-diol had less seizure activity than those administered 
      vehicle. Flutamide had no effects. T is aromatized to 17beta-estradiol (E(2)), 
      which, like 3alpha-diol, acts at estrogen receptors (ERs). Selective estrogen 
      receptor modulators that favor ERalpha (propyl pyrazole triol, 17alpha-E(2)) or 
      ERbeta (diarylpropionitrile, coumestrol, 3alpha-diol), or both (17beta-E(2)), 
      were administered (0.1 mg/kg, SC) to juvenile male rats 1 hour before 
      pentylenetetrazol. Estrogens with activity at ERbeta, but not those selective for 
      ERalpha, produced antiseizure effects. Actions at ERbeta may underlie some 
      antiseizure effects of T's metabolites.
FAU - Frye, Cheryl A
AU  - Frye CA
AD  - Department of Psychology, University at Albany-SUNY, Albany, NY 12222, USA. 
      cafrye@albany.edu
FAU - Ryan, Allicia
AU  - Ryan A
FAU - Rhodes, Madeline
AU  - Rhodes M
LA  - eng
PT  - Journal Article
DEP - 20091023
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
RN  - 0 (Androgen Antagonists)
RN  - 0 (Anticonvulsants)
RN  - 0 (Estrogen Receptor beta)
RN  - 25126-76-5 (Androstane-3,17-diol)
RN  - 4TI98Z838E (Estradiol)
RN  - 76W6J0943E (Flutamide)
RN  - WM5Z385K7T (Pentylenetetrazole)
SB  - IM
MH  - Analysis of Variance
MH  - Androgen Antagonists/pharmacology
MH  - Androstane-3,17-diol/*therapeutic use
MH  - Animals
MH  - Anticonvulsants/*therapeutic use
MH  - Disease Models, Animal
MH  - Estradiol/*therapeutic use
MH  - Estrogen Receptor beta/drug effects/*metabolism
MH  - Flutamide/pharmacology
MH  - Male
MH  - Pentylenetetrazole/pharmacology
MH  - Rats
MH  - Rats, Long-Evans
MH  - Reaction Time/drug effects
MH  - Seizures/chemically induced/*prevention & control
EDAT- 2009/10/27 06:00
MHDA- 2010/02/17 06:00
CRDT- 2009/10/27 06:00
PHST- 2009/07/14 00:00 [received]
PHST- 2009/09/03 00:00 [revised]
PHST- 2009/09/06 00:00 [accepted]
PHST- 2009/10/27 06:00 [entrez]
PHST- 2009/10/27 06:00 [pubmed]
PHST- 2010/02/17 06:00 [medline]
AID - S1525-5050(09)00508-3 [pii]
AID - 10.1016/j.yebeh.2009.09.008 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2009 Nov;16(3):418-22. doi: 10.1016/j.yebeh.2009.09.008. Epub 
      2009 Oct 23.